Nebenwirkungen · Taxotere
TAXOTERE 80 mg/2 mL concentrate and solvent for solution for infusion · Abschnitt 4.8 · PDF-Seite 63–64
HOS-084699 · Präparat HOS-083047
63 MedDRA system organ classes Very common adverse Common adverse reactions reactions Immune system disorders Hypersensitivity (G3/4: 0.6%) Metabolism and nutrition Anorexia (G3/4: 0.6%) disorders Nervous system disorders Peripheral sensory neuropathy Peripheral motor neuropathy (G3/4: 1.2%); (G3/4: 0%) Dysgeusia (G3/4: 0%) Eye disorders Lacrimation increased (G3/4: 0.6%) Cardiac disorders Cardiac left ventricular function decrease (G3/4: 0.3%) Respiratory, thoracic and Epistaxis (G3/4: 0%); mediastinal disorders Dyspnoea (G3/4: 0.6%); Cough (G3/4: 0%) Gastrointestinal disorders Nausea (G3/4: 2.4%); Diarrhoea (G3/4: 1.2%); Stomatitis/Pharyngitis (G3/4: 0.9%); Vomiting (G3/4: 1.2%) Skin and subcutaneous tissue Alopecia; Exfoliative rash (G3/4: 0.3%) disorders Nail disorders (no severe) Musculoskeletal and connective Arthralgia (G3/4: 0.3%); bone disorders Myalgia (G3/4: 0.3%) General disorders and Fatigue (G3/4: 3.9%); administration site conditions Fluid retention (severe: 0.6%)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T16:45:00Z · SHA-256 518a48b73ebbaf067647805c9944cdf9fe7e9826b63e3719c8c44fa589fb5cce · Passage 755455205c94777a46077bcf2d1b41c4e6bfb037bb54a14a5585e3d1c7c3810d · Zeichen 24073–25968 im Abschnitt